Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
Yeh, P., Hunter, T., Sinha, D. et al.
Several novel therapeutics are poised to change the natural history of chronic lymphocytic leukaemia (CLL) and the increasing use of these therapies has highlighted limitations of traditional disease monitoring methods. Here we demonstrate that circulating tumour DNA (ctDNA) is readily detectable in patients with CLL. Importantly, ctDNA does not simply mirror the genomic information contained within circulating malignant lymphocytes but instead parallels changes across different disease compartments following treatment with novel therapies. Serial ctDNA analysis allows clonal dynamics to be monitored over time and identifies the emergence of genomic changes associated with Richter's syndrome (RS). In addition to conventional disease monitoring, ctDNA provides a unique opportunity for non-invasive serial analysis of CLL for molecular disease monitoring.
Yeh, P., Hunter, T., Sinha, D. et al. "Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia" Nature Communications (2017): 14,756